Genopathy
Gene-Disorder Association · Article
Gene
TLR3
Toll Like Receptor 3
Disorder
Human Immunodeficiency Virus Type 1
First reported 2012
Supporting publications 2
Key publication · gene–disorder A common polymorphism in TLR3 confers natural resistance to HIV-1 infection.Journal of immunology (Baltimore, Md. : 1950) · 2012
Key publication · disorder Variable and conserved neutralization antigens of human immunodeficiency virus.Nature · 1986
Manually curatedApproved treatment annotated
Association Review

In brief

The association between TLR3 (Toll Like Receptor 3) and Human Immunodeficiency Virus Type 1 is well established and manually curated, with its 3 contributing sources — 2 of them expert-curated — recording a known molecular basis and a susceptibility locus.

Sources 3
Clinical variants 6
Symptoms 2
Compounds 1
Trials 63of 230 via TLR3 compounds
Publications 2
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

3 sources

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
TLR3

The gene

2 source summaries

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Human Immunodeficiency Virus Type 1

The disorder

5 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
ClinVar and variant evidence

Genetic basis

6 clinical variants

ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.

Request access
06
Interventions

Therapeutics

1 compound or drug

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
07
Human studies

Clinical trials

230 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
08
Literature

Reading

2 publications

Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.

Request access
09
Provenance

References & sources

10 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access